Biomarker NTRK Coverage from Every Angle
Advertisement
Advertisement

Study Update of Larotrectinib in Adults With TRK Fusion–Positive Cancer

By: Cordi Craig, MS
Posted: Monday, November 15, 2021

NTRK gene fusions are oncogenic drivers in various tumor types, and previous studies have reported that larotrectinib, a selective central nervous system (CNS)-active TRK inhibitor, is effective for many patients with TRK fusion–positive cancer. An updated analysis with longer follow-up, presented during the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract 535P), demonstrated continued efficacy with “extended survival benefits” in this patient population, including those with CNS metastases.

“These data reinforce the use of routine NTRK gene fusion testing in patients with solid tumors,” Marcia S. Brose, MD, PhD, of the University of Pennsylvania, Philadelphia, and colleagues concluded.

To evaluate the safety and efficacy of larotrectinib, the researchers analyzed 140 patients with non-CNS TRK fusion–positive cancer who had received treatment. Analyses were conducted across 20 tumor types.

The overall response rate was 67%. Of those responses, 12% were complete responses and 55% were partial responses. In 15 patients with baseline CNS metastases, the overall response rate was 73%. Stable disease and progressive disease were reported in 20% and 9% of patients, respectively. At a median follow-up of 23.2 months, the median duration of response was 49.3 months across all patients. The median progression-free survival was 25.8 months. At a median follow-up of 24.0 months, the median overall survival had not been reached, although the 36-month overall survival rate was 66%.

The duration of treatment ranged from 0.03 months to more than 60.4 months. No new safety signals were identified. Severe treatment-related adverse events were reported in 17 patients (12%). A single patient discontinued treatment due to a treatment-related adverse event.

Disclosure: For full disclosures of the study authors, visit oncologypro.esmo.org.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.